Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Moffitt Cancer Center
Tampa, Florida, United States
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
- Montefiore Medical Center
The Bronx, New York, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- Oregon Health & Science University
Portland, Oregon, United States
- University of Tx Southwestern
Dallas, Texas, United States
- University of Virginia
Charlottesville, Virginia, United States
- University of Washington
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Mar 2019
- Primary completion
- 27 Nov 2020
- Completion
- 5 Oct 2022
- Last update posted
- 19 Sept 2024
- Registered enrollment
- 43
- Registry id
- NCT03532451
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.